



**GMMM** Interface Prescribing  
Subgroup



**Agenda**

**12<sup>th</sup> May 2016, 1pm-3pm**

**Room 410, Number One Riverside, 4th Floor, Smith Street, Rochdale,  
OL16 1XU**

**Declarations of Interest**

(Members may be excluded from discussion/decision making where appropriate – to be recorded in minutes)

Apologies:

	<b>ENC</b>
<b>1) Draft Minutes of April 2016</b>	Item 1
<b>2) Matters Arising</b> <ul style="list-style-type: none"> <li>a) RAG List Recommendations from Jan 2016 meeting – approved at April 2016 GMMM meeting.</li> <li>b) RAG List Recommendations from Feb 2016 meeting - awaiting GMMM approval at May 2016 meeting</li> <li>c) RAG List Recommendations from March 2016 meeting - comments received</li> <li>d) RAG List Recommendations from April 2016 meeting – currently out for comment until 31<sup>st</sup> May 2016</li> <li>e) Azathioprine in ILD SCP – approved at April 2016 GMMM approval meeting</li> <li>f) Oral atypical antipsychotics SCP – approved at April 2016 GMMM approval meeting</li> <li>g) Azathioprine for IBD in paediatrics SCP - awaiting GMMM approval at May 2016 meeting</li> <li>h) Typical antipsychotic depot injections - awaiting GMMM approval at May 2016 meeting</li> </ul>	Item 2c
<b>3) Drugs requiring a review of RAG status</b> <ul style="list-style-type: none"> <li>• Sucroferric Oxyhydroxide</li> <li>• Olanzapine for eating disorders in children &amp; young people</li> </ul>	
<b>4) New Drugs from NTS and Formulary Subgroup Requiring a RAG Status</b> <ul style="list-style-type: none"> <li>• Sacubitril / Valsartan</li> <li>• Guanfacine</li> <li>• Idarucizumab</li> </ul>	Item 4a Item 4b Item 4c
<b>5) Shared Care Protocols – drafts currently out for comment to CCG/Trusts</b> <ul style="list-style-type: none"> <li>• Goserelin in breast cancer</li> </ul>	Item 5

<b>6) Shared Care Protocols – comments received</b> <ul style="list-style-type: none"> <li>• Apomorphine</li> <li>• Amiodarone in paediatrics</li> </ul>	Item 6a Item 6b
<b>7) Shared Care Protocols – 1<sup>st</sup> draft</b> <ul style="list-style-type: none"> <li>• Growth hormone in paedes</li> <li>• Hydroxychloroquine in Dermatology</li> <li>• Azathioprine in Dermatology</li> <li>• Ciclosporin in Dermatology</li> <li>• Mycophenolate in Dermatology</li> </ul>	Item 7a – to follow Item 7b Item 7c Item 7d Item 7e
<b>8) Methylphenidate SCP – use of methylphenidate XL in combination with methylphenidate IR</b>	
<b>9) Update to GMMMG CAMHS SSRI Shared Care Protocols Approved in Oct 2015</b>	Item 9
<b>10) Updates from other groups</b>	
a) Formulary Subgroup (verbal)	
b) New Therapies Subgroup (verbal)	
c) GMMMG (verbal)	
<b>11) AOB</b>	
<b>Date of Next Meeting: 9<sup>th</sup> June 2016, 1pm-3pm, Room 410, Number One Riverside, 4th Floor, Smith Street, Rochdale, OL16 1XU</b>	